FDA Approves Roche's Tecentriq As Adjuvant Treatment For Early Non-small Cell Lung Cancer
16/10 15:24
(RTTNews) - The US Food and Drug Administration has approved Roche's (RHHBY) Tecentriq or atezolizumab as adjuvant treatment, following surgery and platinum-based chemotherapy, for adults with Stage II-IIIA non-small cell lung cancer (NSCLC) whose tumours express PD-L1=1%, as det...